ERBB2 and breast cancer: Taken together, this suggests that the use of trastuzumab-containing neoadjuvant chemotherapy regimens for patients presenting with clinically node positive, HER2-overexpressing breast cancer could provide important information regarding prognosis based on the extent of residual disease.